Stay updated on CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial
Sign up to get notified when there's something new on the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page.

Latest updates to the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedA minor page revision was applied, moving from v3.4.1 to v3.4.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check20 days agoChange DetectedOnly a page revision update from v3.4.0 to v3.4.1 is visible; no core content or study data changes were detected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check27 days agoChange DetectedUI and metadata elements were updated, including a visible 'Show glossary' label and capitalization adjustments to the QC-related update text. A site revision banner now shows v3.4.0, replacing the previous v3.3.4.SummaryDifference0.1%

- Check42 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4; no substantive changes to study data, eligibility, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check63 days agoChange DetectedThe page's Locations section has been expanded to include new sites across the United States and international locations such as Australia and European regions. This broadens the list of enrolling centers and may affect where patients can participate.SummaryDifference2%

- Check91 days agoChange DetectedPublications note updated to state that PubMed entries are automatically filled from PubMed and may or may not pertain to the study, replacing the previous wording. The revision/version tag was updated to v3.3.2.SummaryDifference0.0%

Stay in the know with updates to CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page.